Loratadine Safety in Patients with Elevated AST/ALT Levels

Assessment of Liver Function Abnormalities

Elevated AST and ALT should prompt evaluation for underlying causes before attributing to medication effects, and initial laboratory testing should include a complete liver panel (ALT, AST, alkaline phosphatase, GGT, total and direct bilirubin, albumin, prothrombin time) 1

Loratadine (Claritin) is a second-generation antihistamine that does not have documented hepatotoxicity in standard clinical use, and is not included in guidelines requiring liver function monitoring, according to the American College of Clinical Pharmacy 1, 2, 3, 4

For patients with mild to moderate liver enzyme elevations, loratadine can be prescribed at standard dosing without specific monitoring requirements, and liver enzymes should be monitored as part of the workup for the underlying cause of elevation, as recommended by the American Association for the Study of Liver Diseases 1
For patients with severe liver enzyme elevations, exercise caution with all medications, including loratadine, and consider alternative non-sedating antihistamines if there are concerns about hepatic metabolism, according to the European Association for the Study of the Liver 1, 5

For patients with mild to moderate liver enzyme elevations, routine monitoring of AST/ALT is sufficient, while for patients with severe liver enzyme elevations, monitor liver function within 1-2 weeks of starting loratadine, as recommended by the American Gastroenterological Association 1, 5
If AST/ALT levels increase significantly after starting loratadine (>2× baseline), consider discontinuation, according to the American College of Gastroenterology 6